Observational studyFrontiers in immunology2026
Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the efficacy and safety of neoadjuvant RC-48 combined with a PD-1 inhibitor in patients with muscle-invasive bladder cancer (MIBC), and to investigate the stratification utility of HER2 expression and tumor-associated tertiary lymphoid structures (TLS) as predictive variables for treatment response and clinical prognosis. Patients and methods: This multicenter retrospective real-world study enrolled 38 patients with MIBC from the First Affiliated Hospital of Nanchang University, the Second Affiliated Hospital of Nanchang University, Jiangxi Cancer Hospital, and Jiangxi Provincial People's Hospital. All patients received at least four cycles of neoadjuvant therapy comprising RC-48 combined with a PD-1 inhibitor, followed by radical cystectomy (RC). The TLS in the pre-treatment specimens was evaluated using hematoxylin-eosin (HE) staining, and the expression level of HER2 was assessed by immunohistochemistry (IHC) method. The primary endpoint was the pathological complete response (pCR) rate, and secondary endpoints included radiographic complete response (CR) rate, disease-free survival (DFS), and overall survival (OS). Results: Among the 38 patients, the pCR rate was 34.2%, and the overall CR rate by radiographic assessment was 36.8%, with a PR rate of 31.6%. After a median follow-up of 18.0 months (range, 9-29 months), the 12-month DFS rate was 89.4% (95% CI: 74.2%-95.9%), and the 12-month OS rate was 100% (95% CI: 100%-100%). HER2 overexpression was significantly associated with a higher objective response rate (ORR) (OR = 22.50, 95% CI: 1.51 - 335.33, p = 0.024). In stratified analyses based on TLS, both TLS-2 (primary lymphoid follicles) and TLS-3 (secondary lymphoid follicles with germinal centers) demonstrated significant associations with higher ORR, with ORs of 20.00 (95% CI: 2.75 - 145.48, p = 0.003) and 36.00 (95% CI: 2.72 - 476.21, p = 0.007), respectively, suggesting that greater TLS with enhanced therapeutic benefit. Furthermore, N1 stage (OR = 0.06, 95% CI: 0.01 - 0.59, p = 0.016), N2 stage (OR = 0.04, 95% CI: 0.00 - 0.62, p = 0.021), and T3 stage (OR = 0.08, 95% CI: 0.01 - 0.46, p = 0.004) were each significantly associated with poorer treatment response. Treatment-related adverse events (TRAEs) were generally manageable. Conclusions: The combination of RC-48 and a PD-1 inhibitor exhibits promising efficacy as a neoadjuvant therapy for MIBC. Both HER2 expression and TLS maturity serve as effective stratification indicators for treatment response and prognosis. These findings support further evaluation of this combined regimen in biomarker-driven prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.